Podcast

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

Author(s):

OncLive Staff

In Partnership With:

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Welcome to OncLive On Air. I'm your host today, Jason Harris. OncLive On Air is a podcast from OncLive, which provides oncology professional with the resources and information they need to provide the best patient care.

In both digital and print formats, OncLive covers every angle of oncology practice, from new technologies to treatment advances to important regulatory decisions.

In today's episode, Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab (Herceptin) as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Sheldon M. Feldman, MD
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
David Rimm, MD, PhD
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
Related Content
Nataliya Uboha, MD, PhD, of Wisconsin School of Medicine
October 28th 2024

The Debate Over the Predictive Utility of PD-L1–Low Expression is Ongoing in ESCC

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Jairam Krishnamurthy, MD, FACP, of University of Nebraska Medical Center
October 25th 2024

Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Xiaojia Wang, MD, oncologist, Department of Breast Medical Oncology, Cancer Hospital, University of Chinese Academy of Sciences, Zhejiang Cancer Hospital
October 24th 2024

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

Sung Gwe Ahn, MD, PhD
October 24th 2024

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer